BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H, Omata M. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003;138:299-306. [PMID: 12585827 DOI: 10.7326/0003-4819-138-4-200302180-00008] [Cited by in Crossref: 217] [Cited by in F6Publishing: 185] [Article Influence: 12.1] [Reference Citation Analysis]
Number Citing Articles
1 Walzer N, Kulik LM. Hepatocellular carcinoma: latest developments. Curr Opin Gastroenterol 2008;24:312-9. [PMID: 18408459 DOI: 10.1097/MOG.0b013e3282fafef3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
2 Jiang S, Liu Y, Wang L, Duan C, Liu M. A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma. World J Surg Oncol. 2013;11:240. [PMID: 24060218 DOI: 10.1186/1477-7819-11-240] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
3 Riedel DJ, Tang LS, Rositch AF. The role of viral co-infection in HIV-associated non-AIDS-related cancers. Curr HIV/AIDS Rep 2015;12:362-72. [PMID: 26152660 DOI: 10.1007/s11904-015-0276-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
4 Cooper CL. Therapeutic Interventions for HIV Infection and Chronic Viral Hepatitis. Clinical Infectious Diseases 2005;41:S69-72. [DOI: 10.1086/429499] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
5 Miyatake H, Kobayashi Y, Iwasaki Y, Nakamura S, Ohnishi H, Kuwaki K, Toshimori J, Hagihara H, Nouso K, Yamamoto K. Effect of Previous Interferon Treatment on Outcome After Curative Treatment for Hepatitis C Virus-Related Hepatocellular Carcinoma. Dig Dis Sci 2012;57:1092-101. [DOI: 10.1007/s10620-011-1934-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
6 Koda M, Tanaka S, Takemura S, Shinkawa H, Kinoshita M, Hamano G, Ito T, Kawada N, Shibata T, Kubo S. Long-Term Prognostic Factors after Hepatic Resection for Hepatitis C Virus-Related Hepatocellular Carcinoma, with a Special Reference to Viral Status. Liver Cancer 2018;7:261-76. [PMID: 30319984 DOI: 10.1159/000486902] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
7 Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, Ikeda K, Osaki Y, Numata K, Nakachi K, Kokudo N, Imanaka K, Nishiguchi S, Okusaka T, Nishigaki Y, Shiomi S, Kudo M, Ido K, Karino Y, Hayashi N, Ohashi Y, Makuuchi M, Kumada H; Peretinoin Study Group. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: A randomized double-blind placebo-controlled study. J Gastroenterol. 2015;50:191-202. [PMID: 24728665 DOI: 10.1007/s00535-014-0956-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
8 Editors of the Drafting Committee for Hepatitis Management Guidelines: The Japan Society of Hepatology. Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology. Hepatol Res. 2013;43:1-34. [PMID: 23332085 DOI: 10.1111/hepr.12020] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.8] [Reference Citation Analysis]
9 Moschos S, Varanasi S, Kirkwood JM. Interferons in the treatment of solid tumors. Cancer Treat Res 2005;126:207-41. [PMID: 16209068 DOI: 10.1007/0-387-24361-5_9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
10 Ikeda K, Kobayashi M, Seko Y, Imai N, Hirakawa M, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer. Hepatol Res 2010;40:1168-75. [PMID: 20849431 DOI: 10.1111/j.1872-034X.2010.00720.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
11 Lin SM, Chu CM. Secondary prevention of hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 2005;20:1475-7. [PMID: 16174061 DOI: 10.1111/j.1440-1746.2005.04016.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
12 Huang L, Li J, Lau WY, Yan J, Zhou F, Liu C, Zhang X, Shen J, Wu M, Yan Y. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:158-164. [PMID: 21871026 DOI: 10.1111/j.1440-1746.2011.06888.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
13 Zhuang PY, Shen J, Zhu XD, Zhang JB, Tang ZY, Qin LX, Sun HC. Direct transformation of lung microenvironment by interferon-α treatment counteracts growth of lung metastasis of hepatocellular carcinoma. PLoS One 2013;8:e58913. [PMID: 23527047 DOI: 10.1371/journal.pone.0058913] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
14 Huan HB, Wu LL, Lau WY, Wen XD, Zhang L, Yang DP, Wang XS, Bie P, Xia F. Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients' data. Oncotarget 2017;8:90291-300. [PMID: 29163828 DOI: 10.18632/oncotarget.18853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Sherman M, Klein A. AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings. Hepatology 2004;40:1465-73. [PMID: 15565604 DOI: 10.1002/hep.20528] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
16 Cooper CL. Therapies for HIV and viral hepatitis coinfection. Expert Rev Anti Infect Ther 2005;3:81-9. [PMID: 15757459 DOI: 10.1586/14787210.3.1.81] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Nishikawa H, Osaki Y, Iguchi E, Koshikawa Y, Ako S, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A. The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation. J Clin Gastroenterol. 2013;47:359-366. [PMID: 23090049 DOI: 10.1097/mcg.0b013e31826be9ad] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 3.1] [Reference Citation Analysis]
18 Kubo S, Tanaka H, Takemura S, Yamamoto S, Hai S, Ichikawa T, Kodai S, Shinkawa H, Shuto T, Hirohashi K. Surgical Treatment for Hepatocellular Carcinoma Detected After Successful Interferon Therapy. Surg Today 2007;37:285-90. [DOI: 10.1007/s00595-006-3403-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
19 Gao X, Zhan M, Wang L, Ding Y, Niu J. Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC. J Hepatocell Carcinoma 2020;7:347-60. [PMID: 33299823 DOI: 10.2147/JHC.S279657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Wang CC, Kao JH. How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma? Expert Opin Pharmacother 2016;17:911-9. [PMID: 26831361 DOI: 10.1517/14656566.2016.1149165] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
21 Moriyama M, Arakawa Y. Treatment of interferon-α for chronic hepatitis C. Expert Opinion on Pharmacotherapy 2006;7:1163-79. [DOI: 10.1517/14656566.7.9.1163] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
22 Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Minami Y, Ueshima K, Haji S. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology 2007;72 Suppl 1:98-103. [PMID: 18087189 DOI: 10.1159/000111714] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 5.1] [Reference Citation Analysis]
23 Sasaki R, Kanda T, Kato N, Yokosuka O, Moriyama M. Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response. World J Hepatol 2018;10:898-906. [PMID: 30631394 DOI: 10.4254/wjh.v10.i12.898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
24 Nishikawa H, Kimura T, Kita R, Osaki Y. Radiofrequency ablation for hepatocellular carcinoma. Int J Hyperthermia. 2013;29:558-568. [PMID: 23937321 DOI: 10.3109/02656736.2013.821528] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
25 Kubo S, Takemura S, Sakata C, Urata Y, Uenishi T. Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus. Liver Cancer. 2013;2:40-46. [PMID: 24159595 DOI: 10.1159/000346214] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
26 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Reference Citation Analysis]
27 Bryant R, Laurent A, Tayar C, van Nhieu JT, Luciani A, Cherqui D. Liver resection for hepatocellular carcinoma. Surg Oncol Clin N Am 2008;17:607-33, ix. [PMID: 18486886 DOI: 10.1016/j.soc.2008.02.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
28 Ishii H, Yamamoto J, Ikari T. Adjuvant treatments for resectable hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2008;15:459-462. [PMID: 18836796 DOI: 10.1007/s00534-008-1359-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
29 Shimada K, Sakamoto Y, Esaki M, Kosuge T, Morizane C, Ikeda M, Ueno H, Okusaka T, Arai Y, Takayasu K. Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol. 2007;14:2337-2347. [PMID: 17503155 DOI: 10.1245/s10434-007-9415-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
30 Nouso K, Matsumoto E, Kobayashi Y, Nakamura S, Tanaka H, Osawa T, Ikeda H, Araki Y, Sakaguchi K, Shiratori Y. Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies. J Gastroenterol Hepatol. 2008;23:453-458. [PMID: 17725599 DOI: 10.1111/j.1440-1746.2007.05120.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
31 Hayashi PH, Di Bisceglie AM. The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. Infect Dis Clin North Am 2006;20:1-25. [PMID: 16527646 DOI: 10.1016/j.idc.2006.01.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
32 Tabone M, Vigano' L, Ferrero A, Pellerito R, Carbonatto P, Capussotti L. Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis. Eur J Surg Oncol 2007;33:61-6. [PMID: 17175128 DOI: 10.1016/j.ejso.2006.10.039] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
33 Kanda T. Interferon-free treatment for HCV-infected patients with decompensated cirrhosis. Hepatol Int 2017;11:38-44. [PMID: 27282879 DOI: 10.1007/s12072-016-9749-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
34 Zhang W, Song TQ, Zhang T, Wu Q, Kong DL, Li Q, Sun HC. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitis. Mol Clin Oncol. 2014;2:1125-1134. [PMID: 25279210 DOI: 10.3892/mco.2014.386] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
35 Igbe I, Shen XF, Jiao W, Qiang Z, Deng T, Li S, Liu WL, Liu HW, Zhang GL, Wang F. Dietary quercetin potentiates the antiproliferative effect of interferon-α in hepatocellular carcinoma cells through activation of JAK/STAT pathway signaling by inhibition of SHP2 phosphatase. Oncotarget 2017;8:113734-48. [PMID: 29371942 DOI: 10.18632/oncotarget.22556] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
36 Shinkawa H, Hasegawa K, Arita J, Akamatsu N, Kaneko J, Sakamoto Y, Kokudo N. Impact of Sustained Virological Response to Interferon Therapy on Recurrence of Hepatitis C Virus-Related Hepatocellular Carcinoma. Ann Surg Oncol 2017;24:3196-202. [DOI: 10.1245/s10434-017-6008-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
37 Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol 2017;8:229-42. [PMID: 28480063 DOI: 10.21037/jgo.2017.03.14] [Cited by in Crossref: 60] [Cited by in F6Publishing: 49] [Article Influence: 15.0] [Reference Citation Analysis]
38 Zhong J, Ma L, Li L. Postoperative therapy options for hepatocellular carcinoma. Scandinavian Journal of Gastroenterology 2014;49:649-61. [DOI: 10.3109/00365521.2014.905626] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
39 Kanda T, Ogasawara S, Chiba T, Haga Y, Omata M, Yokosuka O. Current management of patients with hepatocellular carcinoma. World J Hepatol. 2015;7:1913-1920. [PMID: 26244066 DOI: 10.4254/wjh.v7.i15.1913] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
40 Li M, Lu C, Cheng J, Zhang J, Cao C, Xu J, Xu J, Pan H, Zhong B, Tucker S. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2009;24:1437-1444. [PMID: 19486255 DOI: 10.1111/j.1440-1746.2009.05863.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
41 Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543-1554. [PMID: 17133492 DOI: 10.1002/hep.21415] [Cited by in Crossref: 252] [Cited by in F6Publishing: 236] [Article Influence: 18.0] [Reference Citation Analysis]
42 Cusnir M, Patt YZ. Novel systemic therapy options for hepatocellular carcinoma. Cancer J 2004;10:97-103. [PMID: 15130269 DOI: 10.1097/00130404-200403000-00005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
43 Minami T, Tateishi R, Shiina S, Nakagomi R, Kondo M, Fujiwara N, Mikami S, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Yoshida H, Koike K. Comparison of improved prognosis between hepatitis B- and hepatitis C-related hepatocellular carcinoma: Comparison between HBV- and HCV- related HCC. Hepatol Res 2015;45:E99-E107. [DOI: 10.1111/hepr.12468] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
44 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 576] [Article Influence: 165.3] [Reference Citation Analysis]
45 Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. Gastroenterology. 2004;127:S159-S166. [PMID: 15508080 DOI: 10.1053/j.gastro.2004.09.030] [Cited by in Crossref: 151] [Cited by in F6Publishing: 122] [Article Influence: 8.9] [Reference Citation Analysis]
46 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 656] [Article Influence: 62.2] [Reference Citation Analysis]
47 Kubo S. Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy. Clin J Gastroenterol 2009;2:65-70. [DOI: 10.1007/s12328-009-0072-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
48 Sumie S, Kawaguchi T, Kawaguchi A, Kuromatsu R, Nakano M, Satani M, Yamada S, Okamura S, Yonezawa Y, Kakuma T, Torimura T, Sata M. Effect of pioglitazone on outcome following curative treatment for hepatocellular carcinoma in patients with hepatitis C virus infection: A prospective study. Mol Clin Oncol 2015;3:115-20. [PMID: 25469280 DOI: 10.3892/mco.2014.435] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
49 Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Tsujimoto T, Kawaratani H, Uemura M, Fukui H. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. Journal of Hepatology 2009;51:315-21. [DOI: 10.1016/j.jhep.2009.04.011] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
50 Ou Q, Yu Y, Li A, Chen J, Yu T, Xu X, Xie X, Chen Y, Lin D, Zeng Q, Zhang Y, Tang X, Yao H, Luo B. Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma. Ann Transl Med 2020;8:230. [PMID: 32309377 DOI: 10.21037/atm.2020.01.32] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
51 Yoshida H, Yoshida H, Goto E, Sato T, Ohki T, Masuzaki R, Tateishi R, Goto T, Shiina S, Kawabe T. Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Int. 2008;2:89-94. [PMID: 19669283 DOI: 10.1007/s12072-007-9020-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
52 Izumi N, Yasuhiro A, Kurosaki M, Onuki Y, Nishimura Y, Inoue K, Ueda K, Tsuchiya K, Nakanishi H, Uchihara M, Miyake S. Development of Hepatocellular Carcinoma after Interferon Therapy in Chronic Hepatitis C. Intervirology 2005;48:59-63. [DOI: 10.1159/000082096] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
53 Hung C, Lee C, Wang J, Tung H, Chen C, Lu S. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol 2005;20:1553-9. [DOI: 10.1111/j.1440-1746.2005.03925.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
54 Jeong SC, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 2007;13:5343-50. [PMID: 17879404 DOI: 10.3748/wjg.v13.i40.5343] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
55 Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:S20-S37. [PMID: 18304676 DOI: 10.1016/j.jhep.2008.01.022] [Cited by in Crossref: 576] [Cited by in F6Publishing: 541] [Article Influence: 44.3] [Reference Citation Analysis]
56 Nagaoki Y, Imamura M, Nishida Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Fujino H, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Miki D, Hiyama Y, Ochi H, Chayama K, Aikata H. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy: NAGAOKI et al.. J Med Virol 2019;91:650-8. [DOI: 10.1002/jmv.25352] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
57 Jang JW. Management of viral hepatitis in patients with hepatocellular carcinoma. J Korean Med Assoc 2013;56:1001. [DOI: 10.5124/jkma.2013.56.11.1001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
58 Kohli V, Singhal A, Elliott L, Jalil S. Antiviral therapy for recurrent hepatitis C reduces recurrence of hepatocellular carcinoma following liver transplantation. Transpl Int. 2012;25:192-200. [PMID: 22151471 DOI: 10.1111/j.1432-2277.2011.01396.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
59 Surveillance group. ; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117:381-403. [PMID: 29074347 DOI: 10.1016/j.jfma.2017.09.007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 11.8] [Reference Citation Analysis]
60 Kubo S, Takemura S, Uenishi T, Yamamoto T, Ohba K, Ogawa M, Hai S, Ichikawa T, Kodai S, Shinkawa H, Tanaka H. Second hepatic resection for recurrent hepatocellular carcinoma in patients with chronic hepatitis C. World J Surg 2008;32:632-8. [PMID: 18210185 DOI: 10.1007/s00268-007-9365-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
61 Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Toshimori J, Kuwaki K, Hagihara H, Onishi H, Miyake Y, Ikeda F, Shiraha H, Takaki A, Iwasaki Y, Kobashi H, Yamamoto K. Evolution of prognostic factors in hepatocellular carcinoma in Japan. Alimentary Pharmacology & Therapeutics 2010;31:407-14. [DOI: 10.1111/j.1365-2036.2009.04179.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
62 Izzo F, Montella M, Orlando AP, Nasti G, Beneduce G, Castello G, Cremona F, Ensor CM, Holtzberg FW, Bomalaski JS, Clark MA, Curley SA, Orlando R, Scordino F, Korba BE. Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. J Gastroenterol Hepatol 2007;22:86-91. [DOI: 10.1111/j.1440-1746.2006.04463.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
63 Craxì A, Cammà C. Does chemotherapy prevent HCV-related hepatocellular carcinoma? Cons. Dig Liver Dis. 2010;42 Suppl 3:S287-S292. [PMID: 20547316 DOI: 10.1016/s1590-8658(10)60518-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
64 Sun P, Yang X, He RQ, Hu QG, Song ZF, Xiong J, Zheng QC. Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: A systematic review of randomized trials. Hepatol Res. 2014;44:259-269. [PMID: 23607290 DOI: 10.1111/hepr.12115] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
65 Ohki T, Sato K, Kondo M, Goto E, Sato T, Kondo Y, Akamatsu M, Sato S, Yoshida H, Koike Y, Obi S. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence. J Viral Hepat 2021. [PMID: 34312954 DOI: 10.1111/jvh.13579] [Reference Citation Analysis]
66 Shiffman ML. Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation. Liver Transpl. 2003;9:S14-S20. [PMID: 14586890 DOI: 10.1053/jlts.2003.50254] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
67 Kanogawa N, Ogasawara S, Chiba T, Saito T, Motoyama T, Suzuki E, Ooka Y, Tawada A, Kanda T, Mikami S. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. J Gastroenterol Hepatol. 2015;30:1197-1204. [PMID: 25682720 DOI: 10.1111/jgh.12925] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
68 Cherqui D, Laurent A, Tayar C, Chang S, Van Nhieu JT, Loriau J, Karoui M, Duvoux C, Dhumeaux D, Fagniez PL. Laparoscopic liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: midterm results and perspectives. Ann Surg 2006;243:499-506. [PMID: 16552201 DOI: 10.1097/01.sla.0000206017.29651.99] [Cited by in Crossref: 229] [Cited by in F6Publishing: 201] [Article Influence: 15.3] [Reference Citation Analysis]
69 Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, Liaw YF. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer. 2004;100:376-382. [PMID: 14716774 DOI: 10.1002/cncr.20004] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 5.3] [Reference Citation Analysis]
70 Zhang CH, Xu GL, Jia WD, Ge YS. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Cancer. 2009;124:2982-2988. [PMID: 19296539 DOI: 10.1002/ijc.24311] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
71 Masuzaki R, Yoshida H, Tateishi R, Shiina S, Omata M. Hepatocellular carcinoma in viral hepatitis: improving standard therapy. Best Pract Res Clin Gastroenterol. 2008;22:1137-1151. [PMID: 19187872 DOI: 10.1016/j.bpg.2008.11.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
72 Manthravadi S, Paleti S, Pandya P. Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis. Int J Cancer. 2017;140:1042-1049. [PMID: 27861842 DOI: 10.1002/ijc.30521] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
73 Miao RY, Zhao HT, Yang HY, Mao YL, Lu X, Zhao Y, Liu CN, Zhong SX, Sang XT, Huang JF. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2010;16:2931-2942. [PMID: 20556841 DOI: 10.3748/wjg.v16.i23.2931] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
74 Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;32:851-858. [PMID: 20659285 DOI: 10.1111/j.1365-2036.2010.04414.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 8.5] [Reference Citation Analysis]
75 Tomimaru Y, Nagano H, Eguchi H, Kobayashi S, Marubashi S, Wada H, Tanemura M, Umeshita K, Hiramatsu N, Takehara T, Doki Y, Mori M. Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol 2010;102:308-14. [DOI: 10.1002/jso.21633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
76 Perry JF, Strasser SI, George J, Farrell GC, Mccaughan GW. Pharmacotherapy of hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 2005;4:2175-85. [DOI: 10.1517/14656566.4.12.2175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
77 Shimomura S, Ikeda N, Saito M, Ishii A, Takashima T, Sakai Y, Yoshikawa S, Aizawa N, Tanaka H, Iwata Y, Enomoto H, Imanishi H, Yamamoto T, Jomura H, Nakamura H, Iijima H, Nishiguchi S. Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma. Hepatol Int 2010;5:559-66. [PMID: 21442053 DOI: 10.1007/s12072-010-9214-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
78 Matar P, Alaniz L, Rozados V, Aquino JB, Malvicini M, Atorrasagasti C, Gidekel M, Silva M, Scharovsky OG, Mazzolini G. Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci. 2009;16:30. [PMID: 19272130 DOI: 10.1186/1423-0127-16-30] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
79 Kudo M, Sakaguchi Y, Chung H, Hatanaka K, Hagiwara S, Ishikawa E, Takahashi S, Kitai S, Inoue T, Minami Y. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology. 2007;72 Suppl 1:132-138. [PMID: 18087194 DOI: 10.1159/000111719] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
80 Kim BK, Han K, Ahn SH. Prevention of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection. Oncology 2011;81:41-9. [DOI: 10.1159/000333258] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
81 Hagihara H, Nouso K, Kobayashi Y, Iwasaki Y, Nakamura S, Kuwaki K, Toshimori J, Miyatake H, Ohnishi H, Shiraha H, Yamamoto K. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Clin Oncol 2011;16:210-20. [DOI: 10.1007/s10147-010-0150-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
82 Reidy DL, Schwartz JD. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials—I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. Anti-Cancer Drugs 2004;15:427-37. [DOI: 10.1097/01.cad.0000127330.21686.26] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
83 Kawaguchi T, Suetsugu T, Ogata S, Imanaga M, Ishii K, Esaki N, Sugimoto M, Otsuyama J, Nagamatsu A, Taniguchi E, Itou M, Oriishi T, Iwasaki S, Miura H, Torimura T. An association between dietary habits and traffic accidents in patients with chronic liver disease: A data-mining analysis. Biomed Rep 2016;4:615-22. [PMID: 27123257 DOI: 10.3892/br.2016.640] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
84 Sun HC, Tang ZY. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol. 2004;130:307-319. [PMID: 15034787 DOI: 10.1007/s00432-003-0530-y] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 3.9] [Reference Citation Analysis]
85 Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T. Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenterol. 2015;21:10314-10326. [PMID: 26420958 DOI: 10.3748/wjg.v21.i36.10314] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
86 Schwartz JD, Beutler AS. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials—II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anti-Cancer Drugs 2004;15:439-52. [DOI: 10.1097/01.cad.0000131140.12228.bb] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
87 . Guideline 4: Management of HCV-infected patients before and after kidney transplantation. Kidney International 2008;73:S53-68. [DOI: 10.1038/ki.2008.87] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
88 . Introduction. Kidney International 2008;73:S6-9. [DOI: 10.1038/ki.2008.83] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
89 Du Y, Su T, Ding Y, Cao G. Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation. Hepat Mon. 2012;12:e6031. [PMID: 23166535 DOI: 10.5812/hepatmon.6031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
90 Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene. 2006;25:3848-3856. [PMID: 16799626 DOI: 10.1038/sj.onc.1209548] [Cited by in Crossref: 109] [Cited by in F6Publishing: 94] [Article Influence: 7.3] [Reference Citation Analysis]
91 Craxì A, Cammà C. Prevention of hepatocellular carcinoma. Clin Liver Dis 2005;9:329-46, viii. [PMID: 15831277 DOI: 10.1016/j.cld.2004.12.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
92 Shimada K, Sano T, Sakamoto Y, Kosuge T. A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy. Cancer. 2005;104:1939-1947. [PMID: 16177997 DOI: 10.1002/cncr.21461] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 4.2] [Reference Citation Analysis]
93 de Oliveria Andrade LJ, D’Oliveira A, Melo RC, De Souza EC, Costa Silva CA, Paraná R. Association between hepatitis C and hepatocellular carcinoma. J Glob Infect Dis. 2009;1:33-37. [PMID: 20300384 DOI: 10.4103/0974-777x.52979] [Cited by in Crossref: 93] [Cited by in F6Publishing: 43] [Article Influence: 9.3] [Reference Citation Analysis]
94 Masuzaki R, Yoshida H, Kato N, Omata M. Hepatitis C and Hepatocellular Carcinoma. In: Carr BI, editor. Hepatocellular Carcinoma. Totowa: Humana Press; 2010. pp. 259-81. [DOI: 10.1007/978-1-60327-376-3_8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
95 Shirabe K, Takeishi K, Taketomi A, Uchiyama H, Kayashima H, Maehara Y. Improvement of Long-Term Outcomes in Hepatitis C Virus Antibody–Positive Patients with Hepatocellular Carcinoma after Hepatectomy in the Modern Era. World J Surg 2011;35:1072-84. [DOI: 10.1007/s00268-011-1013-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
96 Gao F, Jing P, Liu J, Lu Y, Zhang P, Han W, Liu G, Ru N, Cui G, Sun C, Che Y, Zhang H, Hu Q, Wang HY, Wu Y, Guan C, Fu Q, Ma Z, Yu B. Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultro-minimum incision personalized intratumoral chemoimmunotherapy. J Hepatocell Carcinoma 2015;2:57-68. [PMID: 27508195 DOI: 10.2147/JHC.S80756] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Zhong JH, Li H, Li LQ, You XM, Zhang Y, Zhao YN, Liu JY, Xiang BD, Wu GB. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol. 2012;38:286-295. [PMID: 22281155 DOI: 10.1016/j.ejso.2012.01.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
98 Riaz IB, Riaz H, Riaz T, Rahman S, Amir M, Badshah MB, Kazi AN. Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment: a meta-analysis of randomized controlled trials. BMC Gastroenterol 2012;12:170. [PMID: 23191943 DOI: 10.1186/1471-230X-12-170] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
99 Zacharoulis D, Hatzitheofilou C, Athanasiou E, Zacharoulis S. Antiangiogenic strategies in hepatocellular carcinoma: current status. Expert Review of Anticancer Therapy 2014;5:645-56. [DOI: 10.1586/14737140.5.4.645] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
100 Shao RX, Otsuka M, Kato N, Taniguchi H, Hoshida Y, Moriyama M, Kawabe T, Omata M. Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways. Gastroenterology 2005;128:86-95. [PMID: 15633126 DOI: 10.1053/j.gastro.2004.09.077] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
101 Miuma S, Miyamoto J, Taura N, Fukushima M, Sasaki R, Haraguchi M, Shibata H, Sato S, Miyaaki H, Nakao K. Influence of Interferon-free Direct-acting Antiviral Therapy on Primary Hepatocellular Carcinoma Recurrence: A Landmark Time Analysis and Time-dependent Extended Cox Proportional Hazards Model Analysis. Intern Med 2020;59:901-7. [PMID: 32238660 DOI: 10.2169/internalmedicine.3382-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
102 Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat. 2010;17:287-292. [PMID: 19732321 DOI: 10.1111/j.1365-2893.2009.01181.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 6.2] [Reference Citation Analysis]
103 Rougier P, Mitry E, Barbare JC, Taieb J. Hepatocellular carcinoma (HCC): an update. Semin Oncol. 2007;34:S12-S20. [PMID: 17449346 DOI: 10.1053/j.seminoncol.2007.01.007] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
104 Komura T, Mizukoshi E, Kita Y, Sakurai M, Takata Y, Arai K, Yamashita T, Ohta T, Shimizu K, Nakamoto Y. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol. 2007;102:1939-1946. [PMID: 17573788 DOI: 10.1111/j.1572-0241.2007.01354.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
105 Zhong J, Zhong Q, Li L, Li H. Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review. Tumor Biol 2014;35:9459-68. [DOI: 10.1007/s13277-014-2443-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
106 Tanaka S, Tamori A, Takemura S, Hamano G, Ito T, Kawada N, Kubo S. Surgical Outcomes in Hepatitis C Virus-Related Hepatocellular Carcinoma: Special Reference to Sustained Virological Responses to Interferon Therapy. The American Surgeon 2017;83:1246-55. [DOI: 10.1177/000313481708301127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
107 Solmi L, Nigro G, Roda E. Therapeutic effectiveness of echo-guided percutaneous radiofrequency ablation therapy with a LeVeen needle electrode in hepatocellular carcinoma. World J Gastroenterol 2006;12:1098-104. [PMID: 16534852 DOI: 10.3748/wjg.v12.i7.1098] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
108 Kagawa T, Keeffe EB. Long-term effects of antiviral therapy in patients with chronic hepatitis C. Hepat Res Treat 2010;2010:562578. [PMID: 21188198 DOI: 10.1155/2010/562578] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
109 Kanda T, Matsuoka S, Moriyama M. Early occurrence and recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after sustained virological response. Hepatol Int. 2018;12:90-93. [PMID: 29619621 DOI: 10.1007/s12072-018-9862-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
110 Kudo M. Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:50-55. [PMID: 22212936 DOI: 10.1159/000333259] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
111 Nakamoto Y, Mizukoshi E, Tsuji H, Sakai Y, Kitahara M, Arai K, Yamashita T, Yokoyama K, Mukaida N, Matsushima K, Matsui O, Kaneko S. Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. Clin Exp Immunol. 2007;147:296-305. [PMID: 17223971 DOI: 10.1111/j.1365-2249.2006.03290.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
112 Kondo Y, Yoshida H, Tateishi R, Shiina S, Mine N, Yamashiki N, Sato S, Kato N, Kanai F, Yanase M. Health-related quality of life of chronic liver disease patients with and without hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22:197-203. [PMID: 17295871 DOI: 10.1111/j.1440-1746.2006.04456.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
113 Hayashi PH, Di Bisceglie AM. The progression of hepatitis B– and C–infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. Medical Clinics of North America 2005;89:345-69. [DOI: 10.1016/j.mcna.2004.08.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
114 Nouso K, Tanaka H, Uematsu S, Shiraga K, Okamoto R, Onishi H, Nakamura S, Kobayashi Y, Araki Y, Aoki N. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol. 2008;23:437-444. [PMID: 17683496 DOI: 10.1111/j.1440-1746.2007.05054.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
115 Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Müllhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg. 2009;96:975-981. [PMID: 19672926 DOI: 10.1002/bjs.6731] [Cited by in Crossref: 108] [Cited by in F6Publishing: 102] [Article Influence: 9.0] [Reference Citation Analysis]
116 Hsu Y, Wu C, Lin J. Hepatitis C Virus Infection, Antiviral Therapy, and Risk of Hepatocellular Carcinoma. Seminars in Oncology 2015;42:329-38. [DOI: 10.1053/j.seminoncol.2014.12.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
117 Kim MN, Han KH, Ahn SH. Prevention of hepatocellular carcinoma: beyond hepatitis B vaccination. Semin Oncol. 2015;42:316-328. [PMID: 25843736 DOI: 10.1053/j.seminoncol.2014.12.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
118 Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology. 2004;127:S62-S71. [PMID: 15508105 DOI: 10.1053/j.gastro.2004.09.017] [Cited by in Crossref: 156] [Cited by in F6Publishing: 130] [Article Influence: 9.2] [Reference Citation Analysis]
119 Ribatti D, Vacca A, Nico B, Sansonno D, Dammacco F. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Cancer Treat Rev. 2006;32:437-444. [PMID: 16870349 DOI: 10.1016/j.ctrv.2006.06.002] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 3.7] [Reference Citation Analysis]
120 Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol. 2009;50:958-968. [PMID: 19303160 DOI: 10.1016/j.jhep.2008.12.023] [Cited by in Crossref: 109] [Cited by in F6Publishing: 97] [Article Influence: 9.1] [Reference Citation Analysis]
121 Okuda H. Hepatocellular carcinoma development in cirrhosis. Best Pract Res Clin Gastroenterol 2007;21:161-73. [PMID: 17223503 DOI: 10.1016/j.bpg.2006.07.002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 3.5] [Reference Citation Analysis]
122 Ishikawa T. Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 2013;19:8861-8866. [PMID: 24379608 DOI: 10.3748/wjg.v19.i47.8861] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
123 Corey KE, Pratt DS. Current status of therapy for hepatocellular carcinoma. Therap Adv Gastroenterol. 2009;2:45-57. [PMID: 21180533 DOI: 10.1177/1756283X08100328] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
124 Nishibatake Kinoshita M, Minami T, Tateishi R, Wake T, Nakagomi R, Fujiwara N, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Shiina S, Koike K. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy. J Hepatol. 2019;70:78-86. [PMID: 30336183 DOI: 10.1016/j.jhep.2018.09.029] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 12.7] [Reference Citation Analysis]
125 Nakayama H, Takayama T. Management before hepatectomy for hepatocellular carcinoma with cirrhosis. World J Hepatol. 2015;7:2292-2302. [PMID: 26380653 DOI: 10.4254/wjh.v7.i20.2292] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
126 Zhuang L, Zeng X, Yang Z, Meng Z. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8:e61361. [PMID: 24069133 DOI: 10.1371/journal.pone.0061361] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
127 Nguyen MH, Keeffe EB. General management. Best Practice & Research Clinical Gastroenterology 2005;19:161-74. [DOI: 10.1016/j.bpg.2004.11.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
128 Teratani T, Yoshida H, Shiina S, Obi S, Sato S, Koike Y, Hamamura K, Akamatsu M, Fujishima T, Imai Y, Kawabe T, Shiratori Y, Omata M. A novel display of reconstruction computed tomography for the detection of small hepatocellular carcinoma. Liver Int 2004;24:619-24. [PMID: 15566513 DOI: 10.1111/j.1478-3231.2004.0959.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
129 van der Meer AJ, Berenguer M. Reversion of disease manifestations after HCV eradication. Journal of Hepatology 2016;65:S95-S108. [DOI: 10.1016/j.jhep.2016.07.039] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 20.0] [Reference Citation Analysis]
130 Tanimoto Y, Tashiro H, Aikata H, Amano H, Oshita A, Kobayashi T, Kuroda S, Tazawa H, Takahashi S, Itamoto T. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection. Ann Surg Oncol. 2012;19:418-425. [PMID: 21710324 DOI: 10.1245/s10434-011-1866-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
131 Koga H. Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors? Cancer. 2003;98:661-667. [PMID: 12910508 DOI: 10.1002/cncr.11576] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
132 Wang J, He XD, Yao N, Liang WJ, Zhang YC. A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. Can J Gastroenterol 2013;27:351-63. [PMID: 23781519 DOI: 10.1155/2013/417894] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
133 Prieto J, Qian C, Sangro B, Melero I, Mazzolini G. Biologic therapy of liver tumors. Surg Clin North Am. 2004;84:673-696. [PMID: 15062668 DOI: 10.1016/s0039-6109(03)00230-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
134 Namiki I, Nishiguchi S, Hino K, Suzuki F, Kumada H, Itoh Y, Asahina Y, Tamori A, Hiramatsu N, Hayashi N. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:347-368. [PMID: 20394674 DOI: 10.1111/j.1872-034x.2010.00642.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
135 . Guideline 2: Treatment of HCV infection in patients with CKD. Kidney International 2008;73:S20-45. [DOI: 10.1038/ki.2008.85] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
136 Nojiri S, Kusakabe A, Fujiwara K, Shinkai N, Matsuura K, Iio E, Miyaki T, Nomura T, Sobue S, Sano H, Hasegawa I, Ohno T, Takahashi Y, Orito E, Joh T. Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma. Cancer Manag Res 2012;4:423-9. [PMID: 23293537 DOI: 10.2147/CMAR.S38684] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
137 Honda M, Yamashita T, Yamashita T, Arai K, Sakai Y, Sakai A, Nakamura M, Mizukoshi E, Kaneko S. Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013;13:191. [PMID: 23587162 DOI: 10.1186/1471-2407-13-191] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
138 Zhuang P, Zhang J, Zhang W, Zhu X, Liang Y, Xu H, Xiong Y, Kong L, Wang L, Wu W, Tang Z, Qin L, Sun H. Long-term interferon-α treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma. J Cancer Res Clin Oncol 2010;136:1891-900. [DOI: 10.1007/s00432-010-0848-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
139 Hsu CS, Chao YC, Lin HH, Chen DS, Kao JH. Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma. Sci Rep. 2015;5:9954. [PMID: 25963067 DOI: 10.1038/srep09954] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
140 Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015;62:1420-1429. [PMID: 25733155 DOI: 10.1016/j.jhep.2015.02.038] [Cited by in Crossref: 139] [Cited by in F6Publishing: 135] [Article Influence: 23.2] [Reference Citation Analysis]
141 van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, Aleman S, Ganne-Carrié N, D'Ambrosio R, Pol S, Trapero-Marugan M, Maan R, Moreno-Otero R, Mallet V, Hultcrantz R, Weiland O, Rutter K, Di Marco V, Alonso S, Bruno S, Colombo M, de Knegt RJ, Veldt BJ, Hansen BE, Janssen HLA. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 2017;66:485-93. [PMID: 27780714 DOI: 10.1016/j.jhep.2016.10.017] [Cited by in Crossref: 148] [Cited by in F6Publishing: 124] [Article Influence: 29.6] [Reference Citation Analysis]
142 Hasegawa K, Takayama T, Ijichi M, Matsuyama Y, Imamura H, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology. 2006;44:891-895. [PMID: 17006925 DOI: 10.1002/hep.21341] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
143 Prenner S, Kulik L. HCC: Where Does HCV Therapy Play a Role? Curr Hepatology Rep 2016;15:17-25. [DOI: 10.1007/s11901-016-0292-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
144 Takami T, Yamasaki T, Saeki I, Matsumoto T, Suehiro Y, Sakaida I. Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. World J Gastroenterol 2016;22:7252-63. [PMID: 27621572 DOI: 10.3748/wjg.v22.i32.7252] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
145 Yamanaka Y, Shiraki K, Miyashita K, Inoue T, Kawakita T, Yamaguchi Y, Saitou Y, Yamamoto N, Nakano T, Nakatsuka A, Yamakado K, Takeda K. Risk factors for the recurrence of hepatocellular carcinoma after radiofrequency ablation of hepatocellular carcinoma in patients with hepatitis C. World J Gastroenterol 2005;11:2174-8. [PMID: 15810088 DOI: 10.3748/wjg.v11.i14.2174] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
146 Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res 2015;45:59-74. [PMID: 24965914 DOI: 10.1111/hepr.12378] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 7.4] [Reference Citation Analysis]
147 Legrand A, Vadrot N, Lardeux B, Bringuier A, Guillot R, Feldmann G. Study of the effects of interferon a on several human hepatoma cell lines: analysis of the signalling pathway of the cytokine and of its effects on apoptosis and cell proliferation. Liver Int 2004;24:149-60. [DOI: 10.1111/j.1478-3231.2004.00899.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
148 Cabibbo G, Petta S, Barbàra M, Missale G, Virdone R, Caturelli E, Piscaglia F, Morisco F, Colecchia A, Farinati F, Giannini E, Trevisani F, Craxì A, Colombo M, Cammà C; ITA.LI.CA study group. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. Liver Int 2017;37:1157-66. [PMID: 28061016 DOI: 10.1111/liv.13357] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 11.5] [Reference Citation Analysis]
149 Funaki M, Kitabayashi J, Shimakami T, Nagata N, Sakai Y, Takegoshi K, Okada H, Murai K, Shirasaki T, Oyama T, Yamashita T, Ota T, Takuwa Y, Honda M, Kaneko S. Peretinoin, an acyclic retinoid, inhibits hepatocarcinogenesis by suppressing sphingosine kinase 1 expression in vitro and in vivo. Sci Rep 2017;7:16978. [PMID: 29208982 DOI: 10.1038/s41598-017-17285-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
150 Kajiwara E, Ooho A, Yamashita N. Effectiveness of biweekly low-dosage peginterferon treatment on the improvement of serum alanine aminotransferase and α-fetoprotein levels: Biweekly peginterferon therapy. Hepatology Research 2012;42:254-63. [DOI: 10.1111/j.1872-034x.2011.00916.x] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
151 Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol. 2010;52:889-894. [PMID: 20395009 DOI: 10.1016/j.jhep.2009.12.041] [Cited by in Crossref: 99] [Cited by in F6Publishing: 96] [Article Influence: 9.0] [Reference Citation Analysis]
152 Yamashiki N, Tateishi R, Yoshida H, Shiina S, Teratani T, Sato S, Mine N, Kondo Y, Kawabe T, Omata M. Ablation therapy in containing extension of hepatocellular carcinoma: a simulative analysis of dropout from the waiting list for liver transplantation. Liver Transpl. 2005;11:508-514. [PMID: 15838878 DOI: 10.1002/lt.20392] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
153 Omata M, Kanda T, Yu M, Yokosuka O, Lim S, Jafri W, Tateishi R, Hamid SS, Chuang W, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao J, Mccaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409-35. [DOI: 10.1007/s12072-012-9342-y] [Cited by in Crossref: 114] [Cited by in F6Publishing: 123] [Article Influence: 12.7] [Reference Citation Analysis]
154 Shimomura S, Nishiguchi S. Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection. Hepatol Res 2012;42:22-32. [PMID: 21951512 DOI: 10.1111/j.1872-034X.2011.00889.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
155 Mulcahy MF. Management of hepatocellular cancer. Curr Treat Options Oncol. 2005;6:423-435. [PMID: 16107245 DOI: 10.1007/s11864-005-0045-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
156 Shindoh J, Hasegawa K, Matsuyama Y, Inoue Y, Ishizawa T, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M, Kokudo N. Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus. J Clin Oncol. 2013;31:766-773. [PMID: 23129744 DOI: 10.1200/jco.2012.44.3234] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
157 Heathcote EJ. Prevention of hepatitis C virus–related hepatocellular carcinoma. Gastroenterology 2004;127:S294-302. [DOI: 10.1053/j.gastro.2004.09.044] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 4.2] [Reference Citation Analysis]
158 Kobayashi T, Ishiyama K, Ohdan H. Prevention of recurrence after curative treatment for hepatocellular carcinoma. Surg Today 2013;43:1347-54. [DOI: 10.1007/s00595-012-0473-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
159 Farrell G, Fan J. Prevention of Hepatocellular Carcinoma. In: Al Knawy B, Reddy K, Bolondi L, editors. Hepatocellular Carcinoma. CRC Press; 2009. pp. 36-61. [DOI: 10.3109/9780203092880-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
160 Clavien PA. Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg. 2007;245:843-845. [PMID: 17522507 DOI: 10.1097/sla.0b013e31805d0788] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
161 Taieb J, Barbare J, Rougier P. Medical treatments for hepatocellular carcinoma (HCC): what’s next? Annals of Oncology 2006;17:x308-14. [DOI: 10.1093/annonc/mdl279] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
162 Okita K, Izumi N, Ikeda K, Osaki Y, Numata K, Ikeda M, Kokudo N, Imanaka K, Nishiguchi S, Kondo S. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. J Gastroenterol. 2015;50:667-674. [PMID: 25209978 DOI: 10.1007/s00535-014-0996-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
163 Sakae M, Kubo S, Takemura S, Sakata C, Uenishi T, Kodai S, Shinkawa H, Urata Y, Ohata K, Kaneda K, Nishioka T, Nozawa A, Suehiro S. Effect of interferon therapy on first and second recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res 2012;42:564-73. [PMID: 22257119 DOI: 10.1111/j.1872-034X.2011.00959.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
164 Huang TS, Shyu YC, Chen HY, Yuan SS, Shih JN, Chen PJ. A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis-related hepatocellular carcinoma. J Viral Hepat. 2013;20:729-743. [PMID: 24010648 DOI: 10.1111/jvh.12096] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
165 Tabrizian P, Schwartz ME. Surgical Management of Hepatocellular Carcinoma. Mt Sinai J Med 2012;79:223-31. [DOI: 10.1002/msj.21307] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
166 Omata M, Yoshida H. Prevention and treatment of hepatocellular carcinoma. Liver Transpl 2004;10:S111-4. [PMID: 14762850 DOI: 10.1002/lt.20046] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
167 Sun P, Dong X, Cheng X, Hu Q, Zheng Q. Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. PLoS One. 2014;9:e102761. [PMID: 25058587 DOI: 10.1371/journal.pone.0102761] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
168 Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, Wu CC, Mok KT, Chen CL, Lee WC, Chau GY, Chen YS, Lui WY, Hsiao CF, Whang-Peng J, Chen PJ; Disease Committee of Adjuvant Therapy for Postoperative Hepatocellular Carcinoma, Taiwan Cooperative Oncology Group, National Health Research Institutes, Zhunan, Taiwan. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg. 2012;255:8-17. [PMID: 22104564 DOI: 10.1097/sla.0b013e3182363ff9] [Cited by in Crossref: 78] [Cited by in F6Publishing: 34] [Article Influence: 8.7] [Reference Citation Analysis]
169 Okuwaki Y, Nakazawa T, Kokubu S, Hidaka H, Tanaka Y, Takada J, Watanabe M, Shibuya A, Minamino T, Saigenji K. Repeat Radiofrequency Ablation Provides Survival Benefit in Patients With Intrahepatic Distant Recurrence of Hepatocellular Carcinoma. Am J Gastroenterol 2009;104:2747-53. [DOI: 10.1038/ajg.2009.414] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
170 Cormier J, Thomas K, Chari R, Pinson C. Management of Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery 2006;10:761-80. [DOI: 10.1016/j.gassur.2005.10.006] [Cited by in Crossref: 60] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
171 Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A, Roda E. Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 2006;12:7239-49. [PMID: 17143937 DOI: 10.3748/wjg.v12.i45.7239] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
172 Toshikuni N, Arisawa T, Tsutsumi M. Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World J Gastroenterol. 2014;20:2876-2887. [PMID: 24659879 DOI: 10.3748/wjg.v20.i11.2876] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
173 Akamatsu M, Yoshida H, Shiina S, Teratani T, Obi S, Tateishi R, Mine N, Kondo Y, Kawabe T, Omata M. Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma. Liver Int. 2006;26:536-542. [PMID: 16761997 DOI: 10.1111/j.1478-3231.2006.01260.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
174 Lipman MM, Cotler SJ. Antiviral Therapy for Hepatitis C. Curr Treat Options Gastroenterol 2003;6:445-53. [PMID: 14585233 DOI: 10.1007/s11938-003-0046-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
175 . Guideline 3: Preventing HCV transmission in hemodialysis units. Kidney International 2008;73:S46-52. [DOI: 10.1038/ki.2008.86] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
176 Nishikawa H, Osaki Y, Iguchi E, Takeda H, Matsuda F, Nakajima J, Sakamoto A, Hatamaru K, Saito S, Nasu A, Kita R, Kimura T. Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol 2013;48:951-65. [PMID: 23065022 DOI: 10.1007/s00535-012-0690-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
177 Ishikawa T. Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World J Gastroenterol. 2008;14:6140-6144. [PMID: 18985803 DOI: 10.3748/wjg.14.6140] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
178 Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T, Omata M. Percutaneous radiofrequency ablation for hepatocellular carcinoma: An analysis of 1000 cases. Cancer 2005;103:1201-9. [DOI: 10.1002/cncr.20892] [Cited by in Crossref: 553] [Cited by in F6Publishing: 481] [Article Influence: 34.6] [Reference Citation Analysis]
179 Kanda T, Nakamoto S, Yokosuka O. Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C? World J Virol 2015;4:178-84. [PMID: 26279979 DOI: 10.5501/wjv.v4.i3.178] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
180 Masuzaki R, Yoshida H, Omata M. Does chemotherapy prevent HCV-related hepatocellular carcinoma? Pros. Digestive and Liver Disease 2010;42:S281-6. [DOI: 10.1016/s1590-8658(10)60517-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
181 Ohkoshi S, Yamagiwa S, Yano M, Takahashi H, Aoki YH, Matsuda Y, Aoyagi Y. Very-Low-Dose Pegylated Interferon a2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention. Case Rep Gastroenterol 2010;4:261-6. [PMID: 20805953 DOI: 10.1159/000318742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
182 Jeong S, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol 2007;13:5188-95. [PMID: 17876889 DOI: 10.3748/wjg.v13.i39.5188] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
183 Kawaoka T, Aikata H, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Tashiro H, Ohdan H, Chayama K. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma: PEGIFN/RBV after treatment for HCC. Journal of Viral Hepatitis 2011;18:e550-60. [DOI: 10.1111/j.1365-2893.2011.01468.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
184 Chi CT, Chen CY, Su CW, Chen PY, Chu CJ, Lan KH, Lee IC, Hou MC, Huang YH. Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan. J Microbiol Immunol Infect 2021;54:385-95. [PMID: 31771822 DOI: 10.1016/j.jmii.2019.09.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
185 Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol. 2014;61:S79-S90. [PMID: 25443348 DOI: 10.1016/j.jhep.2014.07.010] [Cited by in Crossref: 124] [Cited by in F6Publishing: 103] [Article Influence: 17.7] [Reference Citation Analysis]